Aviv Regev

Computational and systems biologist Aviv Regev focuses on developing and applying experimental methods and computational algorithms to decipher intra- and intercellular circuits in cells in tissues. She is a pioneer of single cell genomics and has leveraged advances in technology to generate new insights in fields including immunology, neurobiology, and cancer.

Regev is currently the Head and Executive Vice President of Genentech Research and Early Development (gRED), where she is responsible for all aspects of gRED’s drug discovery and development. Regev is also a member of the Genentech Executive Committee and Board of Directors, and a member of the expanded Corporate Executive Committee for Roche.

Prior to Genentech, Regev served as Professor of Biology at MIT, as well as an Investigator at the Howard Hughes Medical Institute. At the Broad Institute of MIT and Harvard, she was also Chair of the Faculty, Core Institute Member, Founding Director of the Klarman Cell Observatory, and member of the Executive Leadership Team. Regev is a founding cochair of the Human Cell Atlas and the author or coauthor of over four hundred peer-reviewed articles.